Geneva Capital Management LLC lowered its holdings in Repligen Corporation (NASDAQ:RGEN – Free Report) by 9.8% during the third quarter, Holdings Channel.com reports. The firm owned 591,711 shares of the biotechnology company’s stock after selling 64,382 shares during the period. Repligen makes up 3.2% of Geneva Capital Management LLC’s holdings, making the stock its 3rd biggest holding. Geneva Capital Management LLC’s holdings in Repligen were worth $113,745,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of Nova Scotia purchased a new stake in Repligen in the second quarter valued at approximately $3,547,000. American Capital Management Inc. acquired a new position in shares of Repligen during the second quarter worth about $49,262,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Repligen during the second quarter worth about $1,173,000. Corient Private Wealth LP increased its stake in shares of Repligen by 420.9% during the second quarter. Corient Private Wealth LP now owns 11,319 shares of the biotechnology company’s stock worth $1,544,000 after buying an additional 9,146 shares during the period. Finally, Tidal Investments LLC increased its stake in shares of Repligen by 75.2% during the second quarter. Tidal Investments LLC now owns 8,863 shares of the biotechnology company’s stock worth $1,209,000 after buying an additional 3,803 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on the stock. Zacks Research cut shares of Repligen from a “strong-buy” rating to a “hold” rating in a report on Monday, September 28th. Weiss Ratings downgraded shares of Repligen from a “hold (c)” rating to a “sell (d+)” rating in a research note on Monday, November 2nd. Royal Bank Of Canada boosted their target price on shares of Repligen from $185.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. Barclays increased their target price on Repligen from $175.00 to $225.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Finally, Canaccord Genuity Group increased their target price on Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a report on Monday, October 19th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $178.57.
View Our Latest Stock Report on Repligen
Repligen Price Performance
RGEN stock opened at $167.79 on Monday. The business has a 50 day moving average price of $177.15 and a 200 day moving average price of $145.67. The stock has a market cap of $10.73 billion, a price-to-earnings ratio of -798.96, a PEG ratio of 2.88 and a beta of 1.11. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $198.87. The company has a quick ratio of 8.43, a current ratio of 9.88 and a debt-to-equity ratio of 0.27.
Repligen (NASDAQ:RGEN – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. The firm had revenue of $209.31 million during the quarter, compared to the consensus estimate of $206.70 million. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.46 earnings per share. Equities research analysts anticipate that Repligen Corporation will post 2.07 earnings per share for the current fiscal year.
Repligen Company Profile
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
Featured Stories
- Five stocks we like better than Repligen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
